Últimas noticias sobre Getty Images Holdings (NYSE:GETY) Bolsa

Getty Images Holdings

Getty Images Holdings Inc is engaged in the core mission of bringing the world's creative and editorial visual content solutions to its customers to engage their audiences. the company has developed market enhancements across e-commerce, content subscriptions, user-generated content, diverse and inclusive content, and proprietary research alongside investment in its technology platform, which includes artificial intelligence and machine learning-driven search functionality and image editing and integrated APIs, to become a trusted industry leader in the visual content. Geographically the company operates in the Americas, Europe, the Middle East, Africa, and Asia-Pacific, out of which a majority of its revenue is generated from the Americas.

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

GETY

SGMO

STNE

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este martes: IHS, HQY, GETY, SGMO y STNE.

5 acciones en el foco este martes: IHS, HQY, GETY, SGMO y STNE

CWCO

SAIC

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este lunes: SAIC, GETY, CTM, CWCO y TSQ.

5 acciones en el foco este lunes: SAIC, GETY, CTM, CWCO y TSQ

Getty Images Holdings, Inc. Class A Common Stock

Getty Images Holdings Inc

Volkswagen AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>) owned luxury car brand, Audi AG is <a target="_blank" href="https://www.benzinga.com/topic/audi" rel="noreferrer noopener">taking steps to secure </a>its future in the face of mounting economic pressures.
On Monday, the German car manufacturer said it reached an agreement with the works council aimed at strengthening the competitiveness and sustainability of its <a target="_blank" href="https://www.audi-mediacenter.com/en/press-releases/management-and-works-council-enter-agreement-for-the-future-16579" rel="noreferrer noopener">operations</a>, particularly in Ingolstadt and Neckarsulm.
The deal focuses on job protection, improved productivity, and a clear technological emphasis, with plans for a quick transition to electric mobility. The new agreement will remain in effect immediately and continue until the end of 2033.
As part of this, Audi will extend its job protection plan until 2033, focusing on creating a more resilient workforce while also targeting reduced labor costs.
The company aims to increase productivity and speed in its production processes through a series of structural changes, which include a reduction of up to 7,500 indirect jobs by 2029.
Xavier Ros, Member of the Audi Board of Management for Human Resources, said, &#8220;We are focusing our team setup and consistently orienting it to the requirements of the future. We are doing this in a socially responsible targeted, step-by-step manner. To this end, we are now entering into a dialog with our employees.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44359600/hyperfine-nvidia-partner-to-make-brain-mris-more-affordable" rel="noreferrer noopener">Hyperfine, Nvidia Partner To Make Brain MRIs More Affordable</a>
Audi is also overhauling its management structure to streamline decision-making processes, reducing bureaucracy, and relying more on digital solutions.
The company is also focusing on cutting down personnel costs by adjusting various forms of compensation, including wage agreements. Key leaders, including Audi&#8217;s management and board, are contributing significantly to this cost-saving effort.
Jörg Schlagbauer, Chairman of Audi&#8217;s General Works Council, said, &#8220;Through a temporary reduction and a new structure of the profit share program, the Audi workforce is giving a major contribution to making the four rings weatherproof and future-proof again. Overall, the Audi workforce is investing many, many millions of euros in its own future over coming years.&#8221;
In terms of long-term investment, Audi is committing 8 billion euros ($8.76 billion) to its German plants by 2029, with a focus on the production of electric vehicles.
In Ingolstadt, a new electric model will be introduced, while in Neckarsulm, the company will boost its AI and digitalization expertise to improve vehicle production.
Additionally, Audi is creating a &#8220;future fund&#8221; of €250 million to help develop new production platforms for future electric models.
The new agreement for the future aims to save Audi over €1 billion annually in the medium term by optimizing its workforce and production strategies.
Price Action: VWAGY shares closed higher by 1.26% at $12.07 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44358047/pepsico-bets-big-on-prebiotic-sodas-with-1-95-billion-poppi-acquisition-details" target="_blank" rel="noreferrer noopener">PepsiCo Bets Big On Prebiotic Sodas With $1.95 Billion Poppi Acquisition: Details</a></li>
</ul>
Image by Valdis Skudre via Shutterstock.

Equities

General

VWAGY

Volkswagen's Audi To Slash Up To 7,500 Jobs By 2029 To Boost Competitiveness

Baird analyst David Rescott maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Outperform and lowers the price target from $707 to $600.

Price Target

Analyst Ratings

ISRG

Baird Maintains Outperform on Intuitive Surgical, Lowers Price Target to $600

WIIM

INDP

Indaptus Therapeutics shares are trading higher after the company started a Phase 1 combination study of Decoy20 with BeiGene's cancer drug for advanced solid tumors.

General Mills, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) will release its third-quarter financial results, before the <a href="https://www.benzinga.com/quote/GIS/earnings">opening bell, on Wednesday, March 19.</a>
Analysts expect the company to report quarterly earnings at 96 cents per share, down from $1.17 per share in the year-ago period. General Mills projects quarterly revenue of $4.95 billion, compared to $5.1 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
With the recent buzz around General Mills, some investors may be eyeing potential gains from the company's dividends, too. Currently, General Mills offers an annual dividend yield of 3.94%. That&#8217;s a quarterly dividend of 60 cents per share ($2.40 a year).  
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $152,350 or around 2,500 shares. For a more modest $100 per month or $1,200 per year, you would need $30,470 or around 500 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($2.40 in this case). So, $6,000 / $2.40 = 2,500 ($500 per month), and $1,200 / $2.40 = 500 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
Price Action: Shares of General Mills gained 2.3% to close at $60.94 on Monday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Image: Shutterstock

Long Ideas

How To Earn $500 A Month From General Mills Stock Ahead Of Q3 Earnings

On Tuesday, Indaptus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) announced it advanced to&nbsp;a new expansion arm of its Phase 1b/2 clinical <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">trial of Decoy20</a>.
The expansion will evaluate the combination of Decoy20 with BeiGene Ltd's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>) PD-1 checkpoint inhibitor, tislelizumab, focusing on safety, dose optimization, and early signs of anti-tumor activity.
<ul>
<li>Initial participants will first receive one week of Decoy20 monotherapy intravenously before starting the combination treatment with Decoy20 + tislelizumab. </li>
<li>The first few patients in the combination phase will be enrolled sequentially to monitor safety. </li>
<li>After review by the trial's Safety Review Committee, unrestricted enrollment will begin. </li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44362322/butterfly-network-is-pioneering-digital-ultrasound-market-analyst-says-undervalued-stock-could-rise-with-growth-execution" rel="noreferrer noopener">Butterfly Network Is ‘Pioneering Digital Ultrasound Market,' Analyst Says Undervalued Stock Could Rise With Growth Execution</a>
Participants will receive both treatments for up to one year or until disease progression, unacceptable toxicity, or withdrawal from the study.
Jeffrey Meckler, CEO of Indaptus, commented, "This marks a pivotal step forward for Indaptus and our Decoy platform. Preclinical research has consistently shown that Decoy20 works synergistically with a checkpoint inhibitor, and we now have the opportunity to test that in patients for the first time."
The company says checkpoint inhibitors such as tislelizumab have improved outcomes in various cancers, but many patients still do not respond or ultimately do not experience a long-lasting effect.
Decoy20 is engineered to activate the immune system in a manner that is theorized to significantly enhance and broaden the effectiveness of checkpoint inhibitors.
As of December 31, 2024, the company had cash and cash equivalents of $5.8 million. In January 2025, the company conducted a private placement, resulting in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44299019/indaptus-therapeutics-reports-fourth-quarter-and-year-end-2024-financial-results-and-provides-corp" rel="noreferrer noopener">net proceeds of $2.0 million</a>.
In February 2025, the company established a $20 million equity line of credit with Yorkville.
The company expects its current cash and cash equivalents to support its ongoing operating activities into the second quarter of 2025.&nbsp;
Price Action: At the last check on Tuesday, INDP stock was down 3.67% at $0.78 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44362710/uk-pharma-industry-trade-association-restores-wegovyozempic-maker-novo-nordisks-membership-after-two-years-of-suspension" target="_blank" rel="noreferrer noopener">UK Pharma Industry Trade Association Restores Wegovy/Ozempic Maker Novo Nordisk's Membership After 2 Years Of Suspension</a></li>
</ul>

Biotech

Health Care

Market-Moving Exclusives

Exclusives

EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors

EXCLUSIVE: Indaptus Therapeutics Tells Benzinga 'New trial arm to evaluate safety, dosing and preliminary anti-tumor activity in advanced solid tumors'

EXCLUSIVE: Indaptus Therapeutics Tells Benzinga Co. Initiates Phase I Combination Study Of Decoy20 With PD-1 Checkpoint Inhibitor Tislelizumab

Barrington Research analyst James Goss maintains Townsquare Media (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSQ#NYSE">TSQ</a>) with a Outperform and maintains $15 price target.

Barrington Research Maintains Outperform on Townsquare Media, Maintains $15 Price Target

Needham analyst Quinn Bolton reiterates Cerence (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>) with a Buy and maintains $16 price target.

Reiteration

CRNC

Needham Reiterates Buy on Cerence, Maintains $16 Price Target

<a href="https://www.cnbc.com/2025/03/18/teslas-china-rival-zeekr-to-roll-out-free-advanced-driver-assistance.html" title="https://www.cnbc.com/2025/03/18/teslas-china-rival-zeekr-to-roll-out-free-advanced-driver-assistance.html">https://www.cnbc.com/2025/03/18/teslas-china-rival-zeekr-to-roll-out-free-advanced-driver-assistance.html</a>

TSLA

CNBC: 'Tesla's China rival Zeekr to roll out advanced driver assistance-system for free'

William Blair analyst Y Katherine Xu downgrades Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Outperform to Market Perform.

Downgrades

INCY

William Blair Downgrades Incyte to Market Perform

MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.50) by 24 percent. This is a 287.5 percent decrease over losses of $(0.16) per share from the same period last year.

Earnings Misses

INKT

MiNK Therapeutics Q4 2024 GAAP EPS $(0.62) Misses $(0.50) Estimate

IHS Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.09 by 711.11 percent. This is a 153.68 percent increase over losses of $(1.36) per share from the same period last year. The company reported quarterly sales of $437.822 million which beat the analyst consensus estimate of $424.001 million by 3.26 percent. This is a 14.12 percent decrease over sales of $509.784 million the same period last year.

Earnings Beats

IHS Holding Q4 2024 GAAP EPS $0.73 Beats $0.09 Estimate, Sales $437.822M Beat $424.001M Estimate

<ul>
<li>The Company intends to use the net proceeds from the Notes offering, together with cash on hand and potentially cash from partially terminating the Company's existing capped call transactions relating to the Company's existing 0.375% Convertible Senior Notes due 2026 (the "Convertible Senior Notes"), (i) to finance the redemption, repurchase, repayment, satisfaction, and discharge or other payment of all or a portion of the Convertible Senior Notes, which may include one or more repurchases pursuant to privately negotiated transactions, and the payment of accrued and unpaid interest thereon, (ii) to pay any fees, costs, and expenses relating to the offering of the Notes and Credit Agreement transactions described below and/or (iii) for general corporate purposes. The Notes offering is subject to market and other conditions, and may not occur as described or at all.</li>
<li>The Company also today announced its intention to amend its existing Credit Agreement to, among other things, extend the maturity of the Company's revolving credit facility from 2028 to 2030 and increase the amount of revolving credit commitments by up to $200 million (resulting in aggregate commitments of up to $500 million). The terms of the commitments and loans under the amended revolving credit facility are expected to be substantially similar to those relating to the commitments and loans under the existing revolving credit facility, except with respect to the aggregate amount of commitments thereunder, the maturity date thereof and certain other terms. The Credit Agreement amendments are subject to market and other conditions, and may not occur as described or at all. The consummation of the Notes offering is not conditioned on the consummation of the Credit Agreement amendments and the consummation of the Credit Agreement amendments are not conditioned on the consummation of the Notes offering</li>
</ul>

Financing

PODD

Insulet Intends To Offer $450M Principal Amount Of Senior Unsecured Notes Due 2033 In A Private Placement

Needham analyst David Saxon reiterates Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) from Hold to Hold.

GMED

Needham Reiterates Hold on Globus Medicalto Hold

Guidance

USEA

United Maritime Says Long-term Fundamentals Of Dry Bulk Market Remain Strong

PYXS

As Of December 31, 2024, Pyxis Oncology Had Cash And Cash Equivalents Of $128.4M That Is Expected To Provide Cash Runway Into The Second Half Of 2026

Pyxis Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.09) by 21.1 percent. This is a 28.65 percent increase over losses of $(1.85) per share from the same period last year. The company reported quarterly sales of $16.15 million which beat the analyst consensus estimate of $13.81 million by 16.89 percent.

Pyxis Oncology FY 2024 GAAP EPS $(1.32) Misses $(1.09) Estimate, Sales $16.15M Beat $13.81M Estimate

UBS analyst Steven Fisher downgrades PACCAR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) from Buy to Neutral and announces $108 price target.

PCAR

UBS Downgrades PACCAR to Neutral, Announces $108 Price Target

NCNO

Sandbox Banking's Glyue Introduced In The Zoom App Marketplace

Legal

Press Releases

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates GETY, NARI, SSY on Behalf of Shareholders

Kuehn Law Encourages VINC, NEUE, GETY, and CLBR Investors to Contact Law Firm

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates GETY, CLBR, VINC, NEUE on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TURN, DFS, GETY on Behalf of Shareholders

Getty Images and Verizon to Award $20,000 Grant to Champion Disability Representation in the Workplace

Getty Images Holdings, Inc. Announces Comprehensive Refinancing of Approximately $1.042 Billion Existing Term Loans

Getty Images to Release Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025

Sports

Getty Images and UEFA Renew Multi-Year Agreement

Getty Images Signs Multi-Year Photography Partnership with the National Women's Soccer League

Getty Images Reports Fourth Quarter and Full Year 2024 Results

CLBR

NARI

NEUE

TURN

VINC

Angi

Bumble

Cars.com

Trump Media & Technology Group Corp. - Warrants

Trump Media & Technology

EverQuote

FuboTV

Nextdoor Holdings, Inc. Class A Common Stock

Nextdoor Holdings

MediaAlpha

Hello Group Inc. - American Depositary Shares

Hello Gr

Outbrain

QuinStreet

Shutterstock

Taboola.com

Tripadvisor

TrueCar

trivago N.V. - American Depositary Shares

trivago

Travelzoo

Vimeo

Vtex

WEBTOON Entertainment Inc. - Common stock

Webtoon Entertainment

Yalla Group Limited American Depositary Shares, each representing one Class A Ordinary Share

Yalla Group

Yelp

Ziff Davis

Zhihu Inc. American Depositary Shares, each representing three (3) Class A Ordinary Shares

Comments

Getty Images Holdings

Noticias

Últimas noticias sobre Getty Images Holdings (NYSE:GETY) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL